Halozyme Therapeutics (HALO) Financial Analysis & Valuation | Quarter Chart
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) ... more
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $14.14B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Helen I. Torley |
| IPO Date | 2004-03-16 | CAGR | 57.77% |
| Employees | 423 | Website | www.halozyme.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.09% | Total Yield | 0.09% |
HALO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $13.07B | P/E | 23.24 | Forward P/E | 11.69 | PEG | 0.85 |
| P/S | 234.53 | P/B | 2681.66 | P/CF | 470.15 | P/FCF | 483.18 |
| Sales | $1.66B | Sales 1Y | 41.15% | Sales 3Y | 115.05% | Sales 5Y | 303.33% |
| EPS | $5.36 | EPS 1Y | -23.34% | EPS 3Y | 95.91% | EPS 5Y | 114.74% |
| Sales QoQ | 27.68% | EPS QoQ | 55.74% | Sales QoQ Avg | 11.84% | EPS QoQ Avg | -80.58% |
| Gross Margin | 78.18% | Operating Margin | 56.77% | Profit Margin | 24.86% | ROCE | 42.3% |
| ROA | 16% | ROE | 181% | Altman Z Score | 5.11 | Piotroski Score | 7 |
| Current Ratio | 2.71 | Quick Ratio | 2.31 | Cash Ratio | 0.47 | Op. CF Ratio | 0.7 |
| Debt/Equity | 14.95 | Debt/Assets | 0.83 | Lt Debt/Equity | 13.5 | Lt Debt/Cap. | 0.93 |
| Intrst Cov. | 103.48 | Inventory Turnover | 2.65 | Asset Turnover | 0.65 | Receivables Turnover | 3.65 |
| Enterprise Value | $13.07B | P/E Ratio | 23.24 |
| Forward P/E | 11.69 | PEG Ratio | 0.85 |
| P/S Ratio | 234.53 | P/B Ratio | 2681.66 |
| P/CF Ratio | 470.15 | P/FCF Ratio | 483.18 |
| EPS | $5.36 | EPS Growth 1Y | -23.34% |
| EPS Growth 3Y | 95.91% | EPS Growth 5Y | 114.74% |
| Revenue Growth 1Y | 41.15% | Gross Margin | 78.18% |
| Operating Margin | 56.77% | Profit Margin | 24.86% |
| ROE | 181% | ROA | 16% |
| ROCE | 42.3% | Current Ratio | 2.71 |
| Quick Ratio | 2.31 | Cash Ratio | 0.47 |
| Debt/Equity | 14.95 | Interest Coverage | 103.48 |
| Altman Z Score | 5.11 | Piotroski Score | 7 |
Halozyme Therapeutics (HALO) valuation & financials
Halozyme Therapeutics (HALO) has a market capitalization of $14.14B and trades at a price-to-earnings ratio of 23.2. It operates in the Healthcare sector (Biotechnology).
Halozyme Therapeutics's revenue grew +41.2% over the last year.
Halozyme Therapeutics's next earnings report is scheduled for November 2, 2026 (provider scheduled date); analysts estimate EPS of $2.30. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)